The Medicines Company has revealed that will present new data from both its antithrombotic range and its investigational hypercholesterolemia trial at the 2015 Scientific Sessions of the American Heart Association, Orlando, USA.
A late breaking clinical trial session will present interim findings from the Phase 1 program on ALN-PCSsc, a ribonucleic acid interference (RNAi) investigational therapy designed to treat hypercholesterolemia by targeting PCSK9. ALN-PCSsc should impede PCSK9 synthesis in the liver, unlike anti-PCSK9 monoclonal antibodies, which bind to protein in the blood. The trial has been conducted by Alnylam Pharmaceuticals under a collaboration agreement with The Medicines Company. Preliminary interim data on ALN-PCSsc were presented at the 2015 European Society of Cardiology (ESC) congress.
Investigators will also present three abstracts on antithrombotic cangrelor (Kengreal), including two new subgroup analyses from the CHAMPION PHOENIX trial of patients undergoing percutaneous coronary intervention (PCI). The first CHAMPION PHOENIX subgroup analysis explores the performance of cangrelor versus clopidogrel in reducing serious ischaemic complications in PCI patients with peripheral artery disease (PAD). The second subgroup analysis evaluates ischaemic risk reduction with cangrelor vs. clopidogrel in the U.S. as compared to non-US patient subgroups.
